The prognostic significance of epidermal growth factor receptor expression in patients with anal carcinoma
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064190%3A_____%2F16%3AN0000078" target="_blank" >RIV/00064190:_____/16:N0000078 - isvavai.cz</a>
Alternative codes found
RIV/00216208:11110/16:10323354 RIV/00216208:11150/16:10323354
Result on the web
<a href="http://dx.doi.org/10.4149/313_150913N485" target="_blank" >http://dx.doi.org/10.4149/313_150913N485</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.4149/313_150913N485" target="_blank" >10.4149/313_150913N485</a>
Alternative languages
Result language
angličtina
Original language name
The prognostic significance of epidermal growth factor receptor expression in patients with anal carcinoma
Original language description
The aim of the present retrospective study was to evaluate the prognostic significance of epidermal growth factor receptor (EGFR) expression in patients treated with radiotherapy or concomitant chemoradiotherapy for squamous cell anal cancer (SCAC) Patients and methods: A total of 17 patients with SCAC (clinical stages I-III) were studies. All patients were treated with radiotherapy (total dose range 40 68 Gy), 13 patients received concomitant chemotherapy (7 patients mitomycin/5-fluorouracil, 5 patients cisplatine/5-fluorouracil, 1 patient cisplatine weekly). EGFR expression in the pretreatment biopsieswas assessed with imunohistochemistry. Patients with EGFR expression had significantly shorter progression free survival (PFS) (p=0.0109; HR 9.38, 95% CI 1.75 - 50.35) and overall survival (OS) (p=0.0351; HR 7.11, 95% CI 1.4 - 36.13) than patients without expression EGFR. The 4-year PFS in patients with increased EGFR expression was only 28.57% (95% CI 17.07 - 62.04%) compared to 87.5% (95% CI 64.58 - 100%) in patients without EGFR expression. The 4-year OS in patients with increased EGFR expression was only 50.0% (95% CI 15.35 - 84.65%) compared to 87.5% (95% CI 64.58 - 100.0%) in patients without EGFR expression. Patients with expression EGFR had significantly shorter PFS and OS compared with patients without EGFR expression.
Czech name
—
Czech description
—
Classification
Type
J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)
CEP classification
FD - Oncology and haematology
OECD FORD branch
—
Result continuities
Project
—
Continuities
V - Vyzkumna aktivita podporovana z jinych verejnych zdroju
Others
Publication year
2016
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
NEOPLASMA
ISSN
0028-2685
e-ISSN
—
Volume of the periodical
63
Issue of the periodical within the volume
3
Country of publishing house
SK - SLOVAKIA
Number of pages
6
Pages from-to
435-441
UT code for WoS article
000377058000013
EID of the result in the Scopus database
2-s2.0-84969670585